[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100445405":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":29,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":29,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":29,"maxAge":29,"enrollmentInfo":58,"targetDuration":29,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":29,"overallStatus":33,"whyStopped":29,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"3 cycles chemotherapy","EXPERIMENTAL","Chemotherapy:vincristine,1.5mg\u002Fm2;carboplatin,560mg\u002F m2;etoposide,150 mg\u002F m2.monthly for the first three months.",[13],"Drug: 3 cycles chemotherapy",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],[19],"vincristine, carboplatin, etoposide",[21],{"name":22,"affiliation":23,"role":24},"Huasheng Yang, M.D, PHD","Zhongshan Ophthalmic Center, Sun Yat-sen University","STUDY_CHAIR",[26],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+8620-87331539",null,"yanghs64@126.com",[32],{"facility":23,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Guangzhou","Guangdong","510000","China","CN",{"type":40,"coordinates":41},"Point",[42,43],113.25,23.11667,{"lat":43,"lon":42},[46],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":48,"investigatorFullName":49,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Huasheng Yang","100445405","phase-3-adjuvant-chemotherapy-for-high-risk-postenucleation-retinoblastoma-100445405",false,"NCT05080010","Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma","Three Cycles of Adjuvant Chemotherapy for the Patients With High-risk Retinoblastoma After Enucleation: Prospective Study","Inclusion Criteria:\n\n* Ability to provide written informed consent and comply with study assessments for the full duration of the study.\n* Definite pathology signs of retinoblastoma, Stage I base on International Retinoblastoma Staging System.\n* Received enucleation in the study eye.\n* Monocular retinoblastoma.\n\nExclusion Criteria:\n\n* Any previous disease in the study eye.\n* Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).\n* History of chemical intervention for retinoblastoma in the study eye.","ALL",{"count":59,"type":60},500,"ESTIMATED","INTERVENTIONAL",[63],"PHASE3","The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.",[66],"Retinoblastoma","2021-10-02",{"date":69,"type":70},"2021-10-15","ACTUAL",{"date":72,"type":70},"2020-11-01",{"date":74,"type":60},"2030-12-31",{"name":5,"class":6},1]